QuickLinks -- Click here to rapidly navigate through this document

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13D/A

Under the Securities Exchange Act of 1934

(Amendment No. 5)*

    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of sections 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g) check the following box / /.

    Note:  Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See Rule 13d-7 for other parties to whom copies are to be sent.

    * The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

---

CUSIP No.  503459109

(1)		NAME OF REPORTING PERSON I.R.S. IDENTIFICATION NO. OF ABOVE PERSON
		Abbott Laboratories IRS Identification No. 36-0698440
(2)		CHECK THE APPROPRIATE BOX IF A		(a)		/ /
		MEMBER OF A GROUP		(b)		/ /
(3)		SEC USE ONLY
(4)		SOURCE OF FUNDS
		Not Applicable
(5)		CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e)  / /
(6)		CITIZENSHIP OR PLACE OF ORGANIZATION
		Illinois
NUMBER OF SHARES				(7)		SOLE VOTING POWER
BENEFICIALLY OWNED						1,603,104
BY EACH REPORTING				(8)		SHARED VOTING POWER
PERSON WITH						0
				(9)		SOLE DISPOSITIVE POWER
						1,603,104
				(10)		SHARED DISPOSITIVE POWER
						0
(11)		AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
		1,603,104
(12)		CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)  / /
(13)		PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
		4.5% (see Item 5 below)
(14)		TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
		CO

---

    The following information amends and supplements the Schedule 13D filed on January 2, 1997 (the "Schedule 13D"), the First Amendment to the Schedule 13D filed on September 26, 1997, the Second Amendment to the Schedule 13D filed on December 17, 1998, the Third Amendment to the Schedule 13D filed on April 17, 2001, and the Fourth Amendment to the Schedule 13D filed on May 24, 2001 (the "Fourth Amendment"). Capitalized terms used herein but not otherwise defined shall have the meanings described in the Schedule 13D.

Item 2.  Identity and Background

    (a)—(c), and (f)  The person filing this statement is Abbott Laboratories ("Abbott"), an Illinois corporation. Abbott's principal business is the discovery, development, manufacture, and sale of a broad and diversified line of health care products and services. Abbott's principal office is located at 100 Abbott Park Road, Abbott Park, Illinois 60064-6049.

    The names, citizenship, business addresses, present principal occupation or employment and the name, and the principal business and address of any corporation or other organization in which such employment is conducted of the directors and executive officers of Abbott are as set forth in Exhibit 1 hereto and incorporated herein by this reference.

    (d) and (e)  Neither Abbott, nor to the best of its knowledge, any person listed on Exhibit 1 has during the last five years (i) been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors) or (ii) been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.

Item 5.  Interest in Securities of the Issuer

    (a)  As of July 20, 2001 Abbott was the beneficial owner of 1,603,104 shares of Common Stock (the "Shares"), representing approximately 4.5% of the outstanding shares of the Common Stock.

    (b)  Abbott has sole power to vote or to direct the vote and the sole power to dispose or to direct the disposition of the Shares.

    (c)  In addition to the sales described in Item 5 of the Fourth Amendment, Abbott has effected the following open market sales of the Common Stock in the past 60 days:

---

Date		Number of Shares Sold		Average Price Per Share
May 23, 2001		5,000		$7.5000
May 25, 2001		5,000		$7.5500
May 29, 2001		2,500		$7.5000
June 7, 2001		12,500		$7.4700
July 2, 2001		9,000		$9.3400
July 3, 2001		15,000		$9.3067
July 5, 2001		3,000		$9.1500
July 9, 2001		10,000		$8.8175
July 10, 2001		68,000		$8.5779
July 20, 2001		870,000		$7.4000

    (d)  No one other than Abbott is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from a sale of, the Shares.

    (e)  On July 20, 2001, Abbott ceased to be the beneficial owner of more than five percent of the Common Stock.

Item 7.  Material to be Filed as Exhibit

    Exhibit 1—Information Concerning Executive Officers and Directors of Abbott Laboratories.

*********************************

Signature

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

		Abbott Laboratories
DATED: July 20, 2001		By: /s/ Thomas C. Freyman Thomas C. Freyman, Senior Vice President, Finance and Chief Financial Officer

---

EXHIBIT INDEX

Exhibit Number		Description
1		Information Concerning Executive Officers and Directors of Abbott Laboratories.

---

QuickLinks

EXHIBIT INDEX

QuickLinks -- Click here to rapidly navigate through this document

Exhibit 1
Information Concerning Executive Officers and
Directors of Abbott Laboratories

    The current corporate officers and directors of Abbott Laboratories are listed below. The address of Abbott Laboratories is: Abbott Laboratories, 100 Abbott Park Road, Abbott Park, Illinois 60064-6049. Abbott Laboratories does not consider all of its corporate officers to be executive officers as defined by the Securities Exchange Act of 1934 or Releases thereunder. Unless otherwise indicated, all positions set forth below opposite an individual's name refer to positions within Abbott Laboratories, and, where applicable, the business address listed for each individual not principally employed by Abbott Laboratories is also the address of the corporation or other organization which principally employs that individual.

Name		Position/Present Principal Occupation or Employment and Business Address		Citizenship
Corporate Officers
Miles D. White1		Chairman of the Board and Chief Executive Officer		U.S.A.
Jeffrey M. Leiden1		Executive President, Pharmaceuticals, Chief Scientific Officer and Director		U.S.A.
Richard A. Gonzalez1		Executive President, Medical Products		U.S.A.
Joy A. Amundson1		Senior Vice President, Ross Products		U.S.A.
Christopher B. Begley1		Senior Vice President, Hospital Products		U.S.A.
Thomas D. Brown1		Senior Vice President, Diagnostic Operations		U.S.A.
Jose M. de Lasa1		Senior Vice President, Secretary and General Counsel		U.S.A.
William G. Dempsey1		Senior Vice President, International Operations		U.S.A.
Thomas C. Freyman1		Senior Vice President, Finance and Chief Financial Officer		U.S.A.
David B. Goffredo1		Senior Vice President, Pharmaceutical Operations		United Kingdom
Thomas M. Wascoe1		Senior Vice President, Human Resources		U.S.A.
Lance B. Wyatt1		Senior Vice President, Specialty Products		U.S.A.
Catherine V. Babington		Vice President, Investor Relations and Public Affairs		U.S.A.
Patrick J. Balthrop		Vice President, Vascular Devices		U.S.A.
Mark E. Barmak		Vice President, Government Affairs		U.S.A.
Michael G. Beatrice		Vice President, Corporate Regulatory and Quality Science		U.S.A.
Christopher A. Bleck		Vice President, Pediatrics, Ross Products		U.S.A.
Douglas C. Bryant		Vice President, Diagnostic Operations, Asia and Pacific		U.S.A.
Gary R. Byers		Vice President, Internal Audit		U.S.A.
Thomas F. Chen		Vice President, Pacific, Asia, and Africa Operations		U.S.A.
Michael Collins		Vice President, Diagnostic Operations		U.S.A.

---

Corporate Officers (Continued)
Edward J. Fiorentino		Vice President, Pharmaceutical Products Commercial Operations		U.S.A.
Gary L. Flynn1		Vice President and Controller		U.S.A.
Stephen R. Fussell		Vice President, Compensation and Development		U.S.A.
Robert B. Hance		Vice President, Diagnostic Operations, Europe, Africa and Middle East		U.S.A.
Guillermo A. Herrera		Vice President, European Operations		Colombia
James J. Koziarz, Ph.D.		Vice President, Diagnostic Products Research and Development		U.S.A.
John C. Landgraf		Vice President, Corporate Engineering		U.S.A.
Elaine R. Leavenworth		Vice President, Washington Government Affairs		U.S.A.
John M. Leonard		Vice President, Global Pharmaceutical Drug Development		U.S.A.
Holger Liepman		Vice President, Japan Operations		Germany
Greg W. Linder		Vice President and Treasurer		U.S.A.
John F. Lussen		Vice President, Taxes		U.S.A.
P. Loreen Mershimer		Vice President, Hospital Products Business Sector		U.S.A.
Edward L. Michael		Vice President, Diagnostic Assays and Systems		U.S.A.
Karen L. Miller		Vice President, Information Technology		U.S.A.
Daniel W. Norbeck		Vice President, Global Pharmaceutical Discovery		U.S.A.
Edward A. Ogunro		Vice President, Hospital Products Research and Development, Medical and Regulatory Affairs		U.S.A.
Roberto Reyes		Vice President, Latin America		Colombia
Mary T. Szela		Vice President, Hospital Products Business Sector		U.S.A.
Marcia A. Thomas		Vice President, Diagnostic Quality Assurance, Regulatory Affairs and Compliance		U.S.A.
James L. Tyree		Vice President, Global Licensing/New Business Development		U.S.A.
Steven J. Weger		Vice President, Corporate Planning and Development		U.S.A.
Susan M. Widner		Vice President, Diagnostic Operations, U.S. and Canada		U.S.A.

---

1

Pursuant to Item 401 (b) of Regulation S-K Abbott has identified these persons as "executive officers" within the meaning of Item 401 (b).

---

Name		Position/Present Principal Occupation or Employment and Business Address		Citizenship
Directors
Roxanne S. Austin		Corporate Senior Vice President and Chief Financial Officer     Hughes Electronics Corporation     P. O. Box 956     200 N. Sepulveda Blvd.     El Segundo, California 90245-0956		U.S.A.
H. Laurance Fuller		Retired Co-Chairman,     BP Amoco, p.l.c.     c/o Primary Business Center     1111 E. Warrenville Road     Suite 257     Naperville, Illinois 60563		U.S.A.
Jack M. Greenberg		Chairman and Chief Executive Officer     McDonald's Corporation     One Kroc Drive     Oak Brook, Illinois 60521		U.S.A.
David A. Jones		Chairman of the Board     Humana Inc.     500 W. Main Street     Humana Building     Louisville, Kentucky 40202		U.S.A.
Jeffrey M. Leiden		Officer of Abbott		U.S.A.
The Rt. Hon. the Lord Owen CH		Physician, Politician, and Businessman     House of Lords     Westminster, London     SW1A 0PW, England		United Kingdom
Boone Powell, Jr.		Chairman     Baylor Health Care System     3500 Gaston Avenue     Dallas, Texas 75246		U.S.A.
Addison Barry Rand		Former Chairman and Chief Executive Officer     Avis Group     900 Old Country Road     Garden City, New York 11530		U.S.A.
Dr. W. Ann Reynolds		President     The University of Alabama     at Birmingham     AB 1070     701 20th Street South     Birmingham, Alabama 35294-0110		U.S.A.
Roy S. Roberts		Retired Group Vice President North American Vehicle Sales, Service and Marketing     General Motors     317 Pine Ridge Drive     Bloomfield Hills, Michigan 48304		U.S.A.

---

Directors (Continued)
William D. Smithburg		Retired Chairman, President and Chief Executive Officer     The Quaker Oats Company     676 N. Michigan Avenue     Suite 3860     Chicago, Illinois 60611		U.S.A.
John R. Walter		Chairman     Manpower, Inc.     5301 N. Ironwood Road     Milwaukee, Wisconsin 53217		U.S.A.
Miles D. White		Officer of Abbott		U.S.A.

---

QuickLinks

Exhibit 1 Information Concerning Executive Officers and Directors of Abbott Laboratories